Across TCGA pan-cancer cohorts, GPATCH3 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GPATCH3 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GPATCH3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GPATCH3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC are the cancer types where GPATCH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	1.000	0.826	.007	5	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: GPATCH3 tumor-vs-normal RNA expression · all GPATCH3 data types